Upadacitinib is a selective Janus kinase 1 inhibitor approved for the treatment of several autoimmune and inflammatory diseases, including moderate-to-severe rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, and ulcerative colitis. This evidence concerns the gene JAK1 and atopic eczema.